Previous Article | Next Article 
Infection and Immunity, October 1999, p. 5076-5082, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Pseudomonas aeruginosa Quorum-Sensing
Signal Molecule
N-(3-Oxododecanoyl)-L-Homoserine Lactone
Inhibits Expression of P2Y Receptors in Cystic Fibrosis Tracheal
Gland Cells
A.
Saleh,1
C.
Figarella,1
W.
Kammouni,1
S.
Marchand-Pinatel,1
A.
Lazdunski,2
A.
Tubul,3
P.
Brun,3 and
M. D.
Merten1,*
Groupe de Recherche sur les Glandes
Exocrines, Faculté de Médecine, 13385 Marseille
05,1 LISM-CNRS, 13402 Marseille Cedex
20,2 Laboratoire de Synthèse
Organique Sélective, GCOPL, Associé au CNRS,
Faculté des Sciences de Luminy, 13288 Marseille Cedex
9,3 France
Received 6 April 1999/Returned for modification 2 June
1999/Accepted 9 July 1999
 |
ABSTRACT |
ATP and UTP have been proposed for use as therapeutic treatment of
the abnormal ion transport in the airway epithelium in cystic fibrosis
(CF), the most characteristic feature of which is permanent infection
by Pseudomonas aeruginosa. As for diverse gram-negative
bacteria, this pathogenic bacterium accumulates diffusible
N-acylhomoserine lactone (AHL) signal molecules, and when a
threshold concentration is reached, virulence factor genes are
activated. Human submucosal tracheal gland serous (HTGS) cells are
believed to play a major role in the physiopathology of CF. Since ATP
and UTP stimulate CF epithelial cells through P2Y receptors, we sought
to determine whether CF HTGS cells are capable of responding to the
AHLs N-butanoyl-L-homoserine lactone (BHL),
N-hexanoyl-L-homoserine lactone (HHL),
N-(3-oxododecanoyl)-L-homoserine lactone
(OdDHL), and N-(3-oxohexanoyl)-L-homoserine
lactone (OHHL), with special reference to P2Y receptors. All AHLs
inhibited ATP- and UTP-induced secretion by CF HTGS cells. The 50%
inhibitory concentrations were as high as 10 and 5 µM for BHL and
HHL, respectively, but were only 0.3 and 0.4 pM for OdDHL and OHHL,
respectively. Furthermore, all AHLs down-regulated the expression of
the P2Y2 and P2Y4 receptors. Ibuprofen and nordihydroguaiaretic acid
were able to prevent AHL inhibition of the responses to nucleotides,
but neither dexamethasone nor indomethacin was able to do this. These
data indicate that AHLs may alter responsiveness to ATP and UTP by CF
HTGS cells and suggest that, in addition to ATP and/or UTP analogues,
ibuprofen may be of use for a combinational pharmacological therapy for CF.
 |
INTRODUCTION |
Cystic fibrosis (CF) is a genetic
disease characterized by hypersecretion of mucus and especially by
persistent severe bacterial infection and inflammation in the airways.
The defect lies in mutations of a membrane protein called CF
transmembrane conductance Regulator (CFTR), which possesses a cyclic
AMP-dependent chloride channel activity (34) that is
defective in CF. However, since calcium-dependent chloride channels
remain functional in CF airway epithelial cells (46), the
use of agents inducing rises in intracellular calcium was proposed for
pharmacological therapy in order to bypass the basic defect in CF.
Among the possible secretagogues acting on the intracellular calcium
pathway, nucleotides such as ATP or UTP analogues are thought to be of
most interest, as they were demonstrated to act on receptors located on
the apical side of the airway epithelium (21). ATP or UTP
analogues were shown to induce chloride secretion by CF epithelial
cells (21) and also to induce bronchial relaxation
(1). When tested clinically, nucleotides or nucleotide
analogues were described as having positive and efficient effects on
mucociliary clearance (3, 29).
The most characteristic feature of CF is the persistent infection of
the airways by the gram-negative bacterium Pseudomonas aeruginosa. This bacterium is a major pathogen in CF which
persists continuously (17) in the airways of CF patients
despite intense antibiotic therapy. A large number of P. aeruginosa virulence factors are regulated by two unique
quorum-sensing systems, LasRI and RhlRI (23, 32). These two
systems form a hierarchical quorum-sensing cascade (23), and
there is considerable overlap within this dual-level control system in
the regulation of many virulence factors. Quorum-sensing systems
generally consist of two components, a small diffusible signal molecule
(N-acylhomoserine lactone [AHL]) and a transcriptional
activator protein (41). When present in sufficient amounts,
the free diffusible signal molecule binds to the regulator, which
activates a set of specific target genes. The threshold concentration
of autoinducer necessary for the induction of the genes is reached when
cultures achieve a sufficiently high bacterial density (for a review,
see reference 15). Two major AHLs
[N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) and N-butanoyl-L-homoserine lactone
(BHL)] and two minor AHLs
[N-(3-oxohexanoyl)-L-homoserine lactone (OHHL)
and N-hexanoyl-L-homoserine lactone (HHL)] have
been identified in P. aeruginosa (47).
Since AHLs appear to readily diffuse across cell membranes
(16), it is possible that these bacterial signal molecules
may influence the physiology of pulmonary epithelial cells and
therefore modulate the possible outcome of infection. This important
aspect, that is, the capacity of bacterial AHLs to be perceived by, and to act upon, not only other bacteria but the eucaryotic host itself, has been largely ignored. Recent findings have shown that the signal
molecule OdDHL could stimulate interleukin-8 (IL-8) production by
respiratory epithelial cells (12) and could also influence the Th1-Th2 balance in the infected host (43). Despite the
fact that these effects have been observed at supramaximal
concentrations (10 to 30 µM), higher than those normally encountered
in laboratory media (33), these data provided us with
preliminary evidence for a contribution of AHLs to the infection process.
Engelhardt et al. (14) have demonstrated that CFTR is almost
undetectable in the surface epithelial cells of the human bronchus, while the serous component of the bronchotracheal glands expresses CFTR
at a very high level. Human tracheal gland serous (HTGS) cells are
responsible for the secretion of antibacterial and antiproteolytic proteins like lactoferrin, lysozyme, and the secretory leukocyte proteinase inhibitor (SLPI) (2). Furthermore, tracheal gland cells are able to respond to nucleotides by stimulation of SLPI secretion (26) and by an increase in chloride transport
(48). The corresponding nucleotide receptors were identified
as P2Y2 and P2Y4 (27). We recently developed a stable cell
line of CF HTGS cells, the CF-KM4 cell line (20). In
culture, these cells were shown to have retained most of their original
epithelial and secretory characteristics, such as constitutive
secretion of SLPI. They have also kept their CF-specific defects, such
as an absence of cyclic AMP-dependent CFTR-associated chloride channel activity and an inability to respond to adrenergic and cholinergic agonists. However, like the original cells, CF-KM4 cells still respond
to nucleotide stimulation. Furthermore, all of these CF-specific defects were shown to be corrected by adenovirus-mediated CFTR gene transfer.
The present work was aimed at determining the possible effects of AHLs
on HTGS cells, with special reference to P2 receptors. We demonstrate
here that the quorum-sensing oxo-AHLs (at up to picomolar
concentrations) dramatically repressed the stimulatory effects of SLPI
secretion by nucleotides, probably due to the repression of P2Y2 and
P2Y4 receptor expression, in CF but not normal HTGS cells. Ibuprofen
(but not glucocorticoids or indomethacin) was able to prevent this
deleterious effect of OdDHL on CF cells. It is therefore possible that
efficiency of pharmacological CF therapy with nucleotide analogues may
be hindered by minimal secretion of the quorum-sensing molecule OdDHL
by P. aeruginosa. However, we suggest that, in addition to
use of ATP or UTP analogues for CF therapy, ibuprofen may be of
potential use for a combinational pharmacological therapy of CF.
 |
MATERIALS AND METHODS |
Chemicals and solutions.
ATP, UTP, epinephrine,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
indomethacin, nordihydrogaiaretic acid (NDGA), dexamethasone,
cortisone, prednisone, ibuprofen, and Dulbecco's modified Eagle's
medium-Ham's F12 medium were obtained from Sigma (St. Louis, Mo.).
Ultroser G was from Biosepra (Villeneuve la Garenne, France). All other
chemicals were of cell culture grade.
Cell culture.
The normal HTGS cell line MM39 (24)
and the CF-KM4 cell line (20) were grown in a Dulbecco's
modified Eagles medium-Ham's F12 medium mixture supplemented with 1%
Ultroser G, 0.22 g of sodium pyruvate per liter, and 8 g of
glucose per liter. Epinephrine (2.5 µM, from a 2.5 mM stock solution
made in 0.001 N HCl and stored at
80°C) was routinely added to the
cell culture medium in order to provide optimal growth and
differentiation. Cells were passaged by using 0.025% trypsin (GIBCO)
and 0.02% EDTA. Type 1 collagen-coated Falcon disposable tissue
culture flasks were used. Adenovirus-mediated CFTR gene transfer in
CF-KM4 cells was carried out as previously described (20).
AHL synthesis.
The general method described by Chhabra et
al. (8) was used to synthesize BHL and HHL, while OdDHL and
OHHL were prepared as described by Dekhane et al. (11). Each
compound was purified by liquid chromatography to homogeneity as
determined by high-pressure liquid chromatography. The structures were
confirmed by infrared as well as 1H and 13C
nuclear magnetic resonance spectroscopy, and their optical purities were controlled by measurement of their optical rotations. The biological activity of each compound was tested as described previously (23).
Cytotoxicity.
The cytotoxicities of the AHLs were assessed
by measuring cellular dehydrogenase activity. Stock solutions of AHLs
(100 µM in dimethyl sulfoxide) were diluted in complete culture
medium. For the cytotoxicity assay, cells were grown until confluency in 24-well tissue culture plates and exposed to the different AHLs for
the durations and at the concentrations indicated in Results. After
incubation, dehydrogenase activity was measured biochemically by using
the water-soluble tetrazolium salt MTT, which is converted to purple
formazan. Results are expressed as changes in optical density compared
to that of a 100% lysis control.
Pharmacological stimulation of SLPI secretion.
Confluent
cultures of CF-KM4 cells grown on 24-well plates were rinsed four times
for 1 h each with serum-free culture medium and then exposed for
30 min to 100 µM nucleotides. Forty microliters of the culture medium
was harvested, and the SLPI was directly measured by enzyme-linked
immunosorbent assay (44). The ratio of the SLPI secreted in
the assays to that secreted in the assays to that secreted in control
experiments was calculated, and agonist-induced stimulations are
expressed as the percentage of SLPI secretion above the control value.
Drugs or vehicle solutions were added at the same times to the
respective wells. Vehicle additions were shown to have no effect on
SLPI secretion by CF-KM4 cells. In each experiment the mean SLPI
secretion rate from quadruplicate assays was determined.
Reverse transcription-PCR amplification.
Total RNA was
purified from cellular pellets of CF-KM4 cells (approximately
107 cells) by the technique of Chomczynski and Sacchi
(9). Total RNA was quantified by absorbance at 260 nm (1 optical density unit = 40 mg/liter), and the quality of the
preparations was monitored by agarose gel electrophoresis in the
presence of formaldehyde. For detection of the expression of P2Y2
(31) and P2Y4 (10) mRNA transcripts, PCR
amplification of mRNA (after conversion to cDNA) was performed with a
Gene AMP RNA PCR kit (Perking-Elmer Cetus). Specific amplifications
were performed with the primers 5'-CTTCAACGAGGACTTCAAGTACGTGC-3'
(nucleotides 323 to 348 of the P2Y2 gene) and
5'-CATGTTGATGGCGTTGAGGGTGTGG-3' (nucleotides 1079 to 1103 of
the P2Y2 gene) for P2Y2 and 5'-ATCCTGCCACCCTCACTTCTCC-3' (nucleotides 137 to 159 of the P2Y4 gene) and
5'-AGGCGAGAAGACGACTGTGC-3' (nucleotides 882 to 902 of the
P2Y4 gene) for P2Y4. Thirty-five cycles of amplification were used,
with cycle times as follows: (i) denaturation for 60 s at 94°C,
(ii) primer annealing for 60 s at 56°C (P2Y2) or 55°C (P2Y4),
and (iii) extension for 150 s at 72°C. An aliquot of the final
amplification solution was analyzed after ethidium bromide staining of
a 2% agarose gel to assess the sizes of the amplified fragments.
Sequences of the PCR products were checked by the dideoxy chain
termination method with a Sequenase sequencing kit (U.S. Biochemical
Corp., Cleveland, Ohio).
Statistics.
All results are expressed as means ± standard deviations (SDs). The significance of differences between the
effects of the concentrations of agents or between the effects of the
agonists was determined by analysis of variance. The difference between agents or between concentrations of agents was isolated by the Scheffé multiple-comparison test.
 |
RESULTS |
Cytotoxicity of AHLs to CF-KM4 cells.
We first checked
for a possible cytotoxic effect of AHLs by using measurements of
cellular dehydrogenase activity through MTT metabolization, which
appeared to be a good method, since HTGS cells were shown to have a
high metabolic activity (25). When added to the cells at up
to 100 µM for 24 h, neither BHL, HHL, OHHL, nor OdDHL showed
cytotoxicity to normal HTGS (MM39) or CF HTGS (CF-KM4) cells (data not shown).
Effects of AHLs on constitutive secretion by CF-KM4 cells.
We
next determined whether AHLs may alter the physiology of HTGS cells.
Since these cells are glandular, we looked for protein secretion by
using SLPI as a representative specific secretory marker. None of the
studied AHLs were found to induce any significant change in the rate of
constitutive secretion of SLPI by MM39 or CF-KM4 cells (data not shown).
Effects of AHLs on regulated secretion by CF-KM4 cells.
We
next looked for effects of AHLs on the ability of cells to be
stimulated by secretagogues for the secretion of SLPI. MM39 cell
secretion can be stimulated by either cholinergic (carbachol), adrenergic (isoproterenol), or purinergic (ATP and UTP) agonists (24, 27). A 100 µM concentration of each secretagogue
gives maximal stimulation of secretion with the following respective values above the control level: 60% ± 12% (P < 0.001), 52% ± 12% (P < 0.001), 65% ± 6%
(P < 0.001), and 60% ± 10% (P < 0.001) (Fig. 1A). CF-KM4 cells do
not respond to carbachol or isoproterenol but are still responsive to
ATP and UTP, with stimulation of 62% ± 6% (P < 0.001) and 65% ± 10% (P < 0.001) above the
control value, respectively (Fig. 1C). Pretreatment of the cells for
24 h with 10 µM OdDHL had no significant effects on MM39 cells
when they were stimulated by any of the secretagogues tested (Fig. 1B). A similar absence of effects was also observed with 10 µM OHHL, HHL,
or BHL (data not shown). However, 1 nM OdDHL led to a total loss of
cell responsiveness to ATP and UTP by CF-KM4 cells (Fig. 1D). Similar
results were obtained with the AHL analogue OHHL (1 nM), and with the
analogues BHL and HHL but at much higher concentrations (10 µM) (data
not shown). To rule out the possibility that the differences seen
between normal (MM39) and CF (CF-KM4) cells were not due to CFTR
differences but to other genetic differences, we repeated the
experiments with the CF-KM4 cells corrected by adenovirus-mediated gene
transfer of CFTR. Under these conditions, the transfected cells showed
the same phenotype as MM39 cells in response to AHLs (data not shown).
This inhibition of the ability of CF-KM4 cells to be stimulated by ATP
was shown to be dependent on the concentration of AHLs. Dose-response
data for the action of OdDHL are presented in Fig.
2. Inhibition was shown to be total up to
an OdDHL concentration of 10
10 M. The concentration
giving half of the maximal inhibition (50% inhibitory concentration
[IC50]) was 0.3 pM. The calculated IC50s were
0.4 pM for OHHL and 10 and 5 µM for BHL and HHL, respectively.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of OdDHL on the ability of MM39 cells (A and B)
and CF-KM4 cells (C and D) to be stimulated by secretagogues. (A and C)
No pretreatment; (B and D) pretreatment with OdDHL. After cells were
cultured to confluency, they were washed and exposed for 30 min to the
secretagogues. For each experiment, secretion of SLPI in response to
100 µM carbachol (Carb.), isoproterenol (Isop.), ATP, and UTP are
presented and expressed as the percentage of SLPI secretion above the
control value (Ctrl). Each bar represents the mean and SD for
quadruplicate determinations from three different experiments
(n = 12). The statistical significance of the
difference between responses to agents and the control are indicated as
follows: **, P < 0.01; ***, P < 0.001. (A) MM39 cells respond to each of the secretagogues with a
significant stimulation of SLPI secretion. (B) Pretreatment of the
cells with 10 µM OdDHL for 24 h does not significantly change
the ability of the MM39 cells to be stimulated by any of the agonists.
(C) CF-KM4 cells do not respond to carbachol and isoproterenol but
still respond to ATP and UTP. (D) Pretreatment of CF-KM4 cells with 1 nM OdDHL for 24 h totally abolishes responsiveness to ATP and
UTP.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Dose dependency of the inhibition by OdDHL of
stimulation of SLPI secretion by ATP. After CF-KM4 cells were cultured
to confluency, increasing concentrations of OdDHL were added and left
for 24 h with the cells. The cells were then washed and exposed
for 30 min to 100 µM ATP. SLPI secretion was determined as described
for Fig. 1. Each bar represents the mean and SD for four experiments
(n = 12). Statistical significance is indicated as
described for Fig. 1.
|
|
Effects of AHLs on P2Y2 and P2Y4 receptor expression by CF-KM4
cells.
Since the stimulatory effects of UTP and ATP were inhibited
by AHLs, and especially by oxo-AHLs, at concentrations not compatible with those expected for receptor antagonists, we checked for the presence of both the P2Y2 and P2Y4 receptors by PCR amplification before and after incubation of CF-KM4 cells with AHLs. We chose primers
from the sequences of the cloned genes in zones with less than 40%
sequence identity between the two receptors (10, 31). Electrophoresis of the PCR products revealed that CF-KM4 cells express
both the P2Y2 and the P2Y4 receptor mRNAs (Fig.
3). Incubation of CF-KM4 cells with BHL
(10 µM) or OdDHL (1 nM) dramatically reduced (for BHL) or completely
inhibited (for OdDHL) the expression of both the P2Y2 and P2Y4
receptors. This inhibition was not due to a general reduction of cell
transcription, since neither of the two AHLs changed the
-actin
transcript levels in CF-KM4 cells (Fig. 3).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of OdDHL and BHL on P2Y2 (A) and P2Y4 (B) mRNA
expression in CF-KM4 cells. Cells were cultured to confluency as
described in the text. Cells were then exposed to 1 nM OdDHL or 10 µM
BHL for 24 h. After total RNA extraction and reverse
transcription, cDNAs were amplified by using primers specific for P2Y2,
P2Y4, and -actin. The amplification products (781 bp for P2Y2 and
765 bp for P2Y4) were separated by electrophoresis on a 2% agarose gel
and stained with ethidium bromide. Ctrl, cells without treatments.
|
|
Effects of anti-inflammatory agents.
Since AHLs were shown to
have immunomodulatory effects (43), we investigated whether
anti-inflammatory agents might be able to modify the inhibitory effects
of OdDHL (1 nM). We analyzed the effects of dexamethasone
(10
7 M), ibuprofen (10 µM), the cyclo-oxygenase
inhibitor indomethacin (10 µM), and the lipo-oxygenase inhibitor NDGA
(10 µM). These agents were added to the cells at the same time as
OdDHL and left to incubate for 24 h. Figure
4 shows that neither dexamethasone nor
indomethacin changed the inhibitory effects of OdDHL. Other glucocorticoids (cortisone and prednisone) gave similar results (data
not shown). However, both NDGA and ibuprofen reversed the inhibitory
effects of OdDHL. We observed a concentration dependence for ibuprofen
prevention of the inhibitory effects of OdDHL (Fig. 5). The IC50 of ibuprofen was
0.8 µM. We also assessed the effects of ibuprofen on the P2Y2
receptor mRNA by PCR amplification before and after CF-KM4 cell
incubation with OdDHL (Fig. 6).
Electrophoresis of the PCR products revealed that ibuprofen (10 µM)
prevented OdDHL-induced inhibition of P2Y2 receptor expression in
CF-KM4 cells. In addition, as for MM39 cells, CF-KM4 cells with
the defect corrected by adenovirus-mediated CFTR gene transfer
expressed the P2Y2 receptor mRNA in presence of 1 nM OdDHL (Fig. 6).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of immunosuppressors on OdDHL-induced inhibition
of secretory responses to ATP by CF-KM4 cells. Confluent CF-KM4 cells
were exposed for 24 h to 1 nM OdDHL with or without 0.1 µM
dexamethasone or 10 µM indomethacin, NDGA, or ibuprofen. The cells
were then washed and exposed for 30 min to 100 µM ATP. The SLPI
secretion was determined as described for Fig. 1. Values are given as
means ± SDs for three experiments (n = 9). Where
no agent was added, only the vehicle was added to the cells.
Statistical significance is indicated as described for Fig. 1. Note
that only NDGA and ibuprofen prevented the inhibition of stimulation of
SLPI secretion by ATP in CF-KM4 cells.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Dose dependency of the prevention by ibuprofen of OdDHL
inhibition of ATP-induced stimulation of SLPI secretion by CF-KM4
cells. Cells grown to confluency were exposed to 1 nM OdDHL and to
increasing concentrations of ibuprofen for 24 h. The cells were
then washed and exposed for 30 min to 100 µM ATP. For each
concentration of ibuprofen tested, secretion of SLPI in response to 100 µM ATP is presented and compared to the control value (Ctrl). Means
and SDs are shown (n = 12). Statistical significance is
indicated as described for Fig. 1.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Effects of OdDHL on P2Y2 mRNA expression in CF-KM4 cells
with the defect corrected by adenovirus-mediated CFTR gene transfer
(Ad-CFTR) or treated with ibuprofen. Cells were cultured to confluency
as described in the text. Cells in absence of OdDHL (A) were compared
to cells exposed to 1 nM OdDHL for 24 h (B). When used, all
products (OdDHL, ibuprofen, or adenovirus) were added to the cells at
the same time. After total RNA extraction and reverse transcription,
cDNAs were amplified by using primers specific for P2Y2 and -actin.
The amplification products were separated by electrophoresis as
described for Fig. 3.
|
|
 |
DISCUSSION |
The aim of the present study was to determine the effects of the
quorum-sensing signal molecules AHLs secreted by P. aeruginosa on normal and CF HTGS cells. Normal cells respond to
cholinergic, adrenergic, and purinergic agonists by an increase in
protein secretion, whereas CF cells are not responsive to adrenergic
and cholinergic agonists but still remain responsive to nucleotides. In
the present paper we show that CF HTGS cells, but not the normal cells,
are no longer able to respond to nucleotides by an increase in the
secretion of SLPI in presence of minute amounts of oxo-AHLs (IC50 of about 0.3 pM). This absence of responsiveness is
related to the repression of both the P2Y2 and P2Y4 receptor mRNAs. It is likely that this excessive sensitivity is related to the CF defect,
since adenovirus-mediated CFTR gene transfer confered resistance to
oxo-AHLs that was similar to that of the normal cells. Another finding
of this study was that ibuprofen was able to prevent the
oxo-AHL-induced repression of P2Y receptors.
In CF, virulence of P. aeruginosa has been demonstrated to
be linked to quorum-sensing density with subsequent relatively high
concentrations of the autoinducers BHL and OdDHL (38). In CF
lungs, P. aeruginosa grows to a high density,
(concentrations of 107 to 108 CFU per g are
common in CF sputa), at which virulence factors are expressed. This
observation suggests that P. aeruginosa has properties which
make the CF lung a good environment for bacterial development and that
quorum-sensing molecules may play a role in chronic infections
associated with CF. P. aeruginosa grows in microcolonies or
in biofilms. These densities of bacteria should produce concentrations
of autoinducers that would trigger the expression of specific target
genes. The role of P. aeruginosa quorum-sensing systems in
infectious processes has not been extensively studied. It has recently
been shown that P. aeruginosa biofilms on indwelling
urethral catheters produce quorum-sensing signal molecules in situ and
in vitro (37). It has also been found that a lasR
mutant is significantly less virulent in a neonatal mouse model of
infection (42) and that the lasR gene is
expressed in the lungs of CF patients (38). Taken together,
these results strongly suggest that quorum-sensing systems may play a
role in infection process by regulating synthesis of several virulence factors. Nevertheless, probably because of technical difficulties, concentrations of AHLs in sputa of CF patients have never been reported. As the concentration of OdDHL normally produced in laboratory media is approximately 5 µM (33), it is reasonable to
postulate that high local concentrations may be attained in sputa of CF patients, because bacteria grow as microcolonies. Since AHLs appear to
readily diffuse across cell membranes, it is conceivable that these
bacterial signal molecules per se may influence the outcome of the
infection by modulating the host cell response. One possibility is that
the quorum-sensing AHLs produced by P. aeruginosa could be
able to modify the behavior of the CF epithelial cells which are
thought to be most implicated in the pulmonary physiopathology of the
disease, i.e., the CF HTGS cells (14). This was the
hypothesis that we wanted to address in this study.
There are relatively few data in the literature regarding the effects
of AHLs on airway cells. The signal molecule OdDHL has been reported by
some authors (12) but not by others (30) to
stimulate IL-8 secretion by respiratory epithelial cells. However, this
effect was observed at very high concentrations of OdDHL (over 10 µM), which are over the quorum-sensing level, and in a physiological
situation where toxins and virulence factors should be secreted by the
bacteria. IL-8 is a potent chemoattractant for neutrophils, whose role,
when activated, is to attack, digest, and destroy bacteria at the site
of infection. However, since in these reports no difference in
OdDHL-induced IL-8 secretion between normal and CF cells was observed,
it is unlikely (i) that this phenomenon is pathological rather than a
positive reaction against infection, and (ii) that this phenomenon
could be involved in the pathophysiology of CF. The reasons for this
specific affinity of P. aeruginosa for the CF airway are
still unclear. Several authors have suggested that P. aeruginosa may bind to some membrane receptors that are
up-regulated in CF epithelial cells (7). However, these
findings were not observed in vivo (45) and hardly explain
the failure of the nonspecific immune system. Other authors have
suggested that the up-regulation of IL-8 and down-regulation of IL-10
found in CF would generate an inflammatory state prone to P. aeruginosa development (5). However, this imbalance in inflammatory cytokines would, rather, protect the lung tissue and
cannot explain the specificity of P. aeruginosa.
In contrast to the above-mentioned data, our results indicate that the
quorum-sensing signal molecules OdDHL and OHHL can inhibit expression
of nucleotide receptors by CF HTGS cells but not by their homologous
normal, non-CF cells. This phenomenon was also observed with BHL and
HHL but at very high concentrations (>10 µM), which are reached only
in vitro (33). The IC50s of OdDHL and OHHL are
very low (0.3 and 0.4 pM, respectively), and since the secretion of
oxo-AHLs by bacteria is proportional to bacterial density, these low
values imply that the presence of only a small amount of bacteria is
needed to lead to dramatic effects on expression of the P2Y2 and P2Y4
receptors. Very large quantities of P. aeruginosa in CF
airways (
107 CFU/g of sputum) are found during infection,
and the quantities are still significant (about 106 CFU/g)
when infection is overcome (18). Therefore, it is possible that, due to this persistence of bacteria, the expression of P2 receptors might be continuously repressed in the airways of CF patients.
The fact that CF gland cells are normally able to respond to
nucleotides by mobilization of intracellular calcium (25a), by an increase in chloride transport (48), and by
stimulation of protein secretion (27) strengthens the case
for the eventual use of nucleotide analogues for therapeutic purposes.
ATP and UTP analogues have already been tested on healthy volunteers
and on CF patients with mild CF injuries. Data about these human trials are scarce; the trials were first performed with CF patients with mild
lung disease, and the data concerned chloride transport in the nose
(22). Furthermore, these results were from experiments performed on epithelial tissue devoid of bacterial contamination, and
no data are available for infected tissue. Currently, clinical trials
are being carried out in the United States and in the United Kingdom
(35). It would be very interesting to know whether and how
much the benefit of the clinical treatment is impaired by infection
and/or by the residual presence of bacteria.
The fact that OdDHL may induce abolition of expression of P2Y2 and P2Y4
receptors by CF-KM4 cells suggests that the action of OdDHL may lead
directly or indirectly to the mobilization of inhibitory transcription
factors involved in the expression of the P2Y genes. One possibility is
that leukotrienes may be involved in that process, since inhibitors of
leukotriene synthesis, but not inhibitors of the cyclo-oxygenase
pathway, inhibited the action of oxo-AHLs. Furthermore, the high
sensitivity of CF HTGS cells to oxo-AHLs, in comparison to the normal
HTGS cells, suggests a CF-specific defect linked with arachidonate
metabolism. It has long been known that there is an alteration of
arachidonate metabolism in CF (39). However, although many
investigations have detailed some cellular mechanisms involved in
phospholipase A2 overactivation in CF (4, 28), neither the
reasons for the overactivation (including the link with the CFTR
defect) nor its physiological consequences have been determined so far.
On the other hand, in contrast to ibuprofen and NDGA, glucocorticoids
were shown to be inefficient in preventing OdDHL negative effects.
Glucocorticoids are known to activate transcription of lipocortin-1,
which is a physiological intracellular inhibitor of phospholipase A2.
Glucocorticoids are thus indirectly able to inhibit generation of
eicosanoides. Both NDGA, by inhibiting lipo-oxygenase, and ibuprofen,
by inhibiting both cyclo-oxygenase and lipo-oxygenase, also inhibit
generation of eicosanoides. Thus, the difference in the effects of (i)
glucocorticoids and (ii) ibuprofen or NDGA is intriguing. A possibility
is that glucocorticoids, in contrast to lipo-oxygenase inhibitors, do not function normally in CF cells. Defective inhibition of leukotriene production by leukocytes in patients with CF was reported
(36), resistance of CF B lymphocytes to dexamethasone was
observed (13), and inefficiency of dexamethasone in
inhibiting lipopolysaccharide-induced cytokine production by CF HTGS
cells was shown (19). Another possibility is that ibuprofen
and NDGA may act through mechanisms other than inhibition of
leukotriene production. Ibuprofen was shown to stabilize the
NF-
B-I
B complex in the cytoplasm (40). NF-
B is a
transcription factor which is located in the cytoplasm in an inactive
form, where it is bound to a protein called inhibitor-
B
(I
B
). Upon stimulation, I
B
is phosphorylated and degraded, resulting in the release and translocation of NF-
B into the nucleus, where it activates the expression of numerous genes. Ibuprofen was
shown to be able to block the degradation of I
B
and thereby to
inhibit activation and translocation of NF-
B into the nucleus (40). NDGA was also shown to inhibit I
B degradation
(6). Further understanding of the molecular mechanism of
ibuprofen action should provide insights into the process of oxo-AHL
action and, more generally, into the emergence of infection and
inflammation in CF patients. Here we have not been able to assess how
oxo-AHLs have this particular action on CF-KM4 cells, but the
consequences of this observation might be relevant. Ibuprofen has been
used with success in decreasing inflammation associated with CF
overinfection. That the negative effect of oxo-AHLs on P2Y expression
was abolished by ibuprofen suggests a possible beneficial effect of ATP
and/or UTP analogues in association with ibuprofen for CF therapy.
In conclusion, the results presented here show that oxo-AHLs from
P. aeruginosa induce the repression of P2Y2 and P2Y4
receptors by CF-KM4 cells. It is our understanding that this work
represents the first demonstration of an effect of AHLs on a secretory
mechanism involved in the lung defense system in CF HTGS cells but not
in normal, non-CF HTGS cells. The ability of ibuprofen to prevent this
deleterious effect suggests that a possible use of ibuprofen in
combination with ATP and/or UTP analogues would be of considerable interest for pharmacological therapy of CF.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the Association
Française de Lutte contre la Mucoviscidose (AFLM). A. Saleh is
the recipient of a fellowship from AFLM.
We thank M. Foglino for fruitful discussions and Anne Shildrake for her
help with the English text.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Groupe de
Recherche sur les Glandes Exocrines, Faculté de Médecine,
27, Bld Jean Moulin, 13385 Marseille 05, France. Phone: 33(0)4
91788260. Fax: 33(0)491786895. E-mail:
grge{at}medecine.univ-mrs.fr.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Aksoy, M. O., and S. G. Kelsen.
1994.
Relaxation of rabbit tracheal smooth muscle by adenine nucleotides: mediation by P2-purinoceptors.
Am. J. Respir. Cell Mol. Biol.
10:230-236[Abstract].
|
| 2.
|
Basbaum, C. B.,
B. Jany, and W. E. Finkbeiner.
1990.
The serous cell.
Annu. Rev. Physiol.
52:97-113[Medline].
|
| 3.
|
Bennett, W. D.,
K. N. Olivier,
K. L. Zeman,
K. W. Hohneker,
R. C. Boucher, and M. R. Knowles.
1996.
Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis.
Am. J. Respir. Crit. Care Med.
153:1796-1801[Abstract].
|
| 4.
|
Berguerand, M.,
E. Klapisz,
G. Thomas,
L. Humbert,
A. M. Jouniaux,
J. L. Olivier,
G. Bereziat, and J. Masliah.
1997.
Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines.
Am. J. Respir. Cell Mol. Biol.
17:481-490[Abstract/Free Full Text].
|
| 5.
|
Bonfield, T. L.,
J. R. Panuska,
M. W. Konstan,
K. A. Hilliard,
J. B. Hilliard,
H. Ghnaim, and M. Berger.
1995.
Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator.
Am. J. Respir. Crit. Care Med.
152:2111-2118[Abstract].
|
| 6.
|
Brennan, P., and L. A. O'Neill.
1998.
Inhibition of nuclear factor kappaB by direct modification in whole cells mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers.
Biochem. Pharmacol.
55:965-973[Medline].
|
| 7.
|
Bryan, R.,
D. Kube,
A. Perez,
P. Davis, and A. Prince.
1998.
Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells.
Am. J. Respir. Cell Mol. Biol.
19:269-277[Abstract/Free Full Text].
|
| 8.
|
Chhabra, S. R.,
P. Stead,
N. J. Bainton,
G. P. Salmond,
G. S. Stewart,
P. Williams, and B. W. Bycroft.
1993.
Autoregulation of carbapenem biosynthesis in Erwinia carotovora by analogues of N-(3-oxohexanoyl)-L-homoserine lactone.
Antibiotics (Tokyo)
46:441-454.
|
| 9.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 10.
|
Communi, D.,
S. Pirotton,
M. Parmentier, and J. M. Boeynaems.
1995.
Cloning and functional expression of a human uridine nucleotide receptor.
J. Biol. Chem.
270:30849-30852[Abstract/Free Full Text].
|
| 11.
|
Dekhane, M.,
K. T. Douglas, and P. Gilbert.
1996.
A novel convenient route to the naturally occuring 3-oxoacyl-L-homoserinelactones and related bacterial autoinducers.
Tetrahedron Lett.
37:1883-1884.
|
| 12.
|
DiMango, E.,
H. J. Zar,
R. Bryan, and A. Prince.
1995.
Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8.
J. Clin. Invest.
96:2204-2210.
|
| 13.
|
Emilie, D.,
M. C. Crevon,
R. Chicheportiche,
M. T. Auffredou,
R. Barot-Ciorbaru,
G. Lenoir,
J. M. Dayer, and P. Galanaud.
1990.
Cystic fibrosis patients' B lymphocyte response is resistant to the in vitro enhancing effect of corticosteroids.
Eur. J. Clin. Invest.
20:620-626[Medline].
|
| 14.
|
Engelhardt, J. F.,
J. R. Yankaskas,
S. A. Ernst,
Y. P. Yang,
C. R. Marino,
R. C. Boucher,
J. A. Cohn, and J. M. Wilson.
1992.
Submucosal glands are the predominant site of CFTR expression in human bronchus.
Nat. Genet.
2:240-248[Medline].
|
| 15.
|
Fuqua, C.,
S. C. Winans, and E. P. Greenberg.
1996.
Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators.
Annu. Rev. Microbiol.
50:727-751[Medline].
|
| 16.
|
Fuqua, W. C.,
S. C. Winans, and E. P. Greenberg.
1994.
Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators.
J. Bacteriol.
176:269-275[Free Full Text].
|
| 17.
|
Hata, J. S., and R. B. Fick, Jr.
1988.
Pseudomonas aeruginosa and the airway disease of cystic fibrosis.
Clin. Chest Med.
9:679-689[Medline].
|
| 18.
|
Jaffar-Bandjee, M. C.,
A. Lazdunski,
M. Bally,
J. Carrere,
J. P. Chazalette, and C. Galabert.
1995.
Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa.
J. Clin. Microbiol.
33:924-929[Abstract].
|
| 19.
|
Kammouni, W.,
C. Figarella,
S. Marchand, and M. D. Merten.
1997.
Altered cytokine production by cystic fibrosis tracheal gland serous cells.
Infect. Immun.
65:5176-5183[Abstract].
|
| 20.
|
Kammouni, W.,
B. Moreau,
F. Becq,
A. Saleh,
A. Pavirani,
C. Figarella, and M. D. Merten.
1999.
A cystic fibrosis tracheal gland cell line, CF-KM4. Correction by adenovirus-mediated CFTR gene transfer.
Am. J. Respir. Cell Mol. Biol.
20:684-691[Abstract/Free Full Text].
|
| 21.
|
Knowles, M. R.,
L. L. Clarke, and R. C. Boucher.
1991.
Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis.
N. Engl. J. Med.
325:533-538[Abstract].
|
| 22.
|
Knowles, M. R.,
L. L. Clarke, and R. C. Boucher.
1992.
Extracellular ATP and UTP induce chloride secretion in nasal epithelia of cystic fibrosis patients and normal subjects in vivo.
Chest
101(Suppl. 3):60S-63S.
|
| 23.
|
Latifi, A.,
M. Foglino,
K. Tanaka,
P. Williams, and A. Lazdunski.
1996.
A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS.
Mol. Microbiol.
21:1137-1146[Medline].
|
| 24.
|
Merten, M.,
W. Kammouni,
W. Renaud,
F. Birg,
M. G. Mattei, and C. Figarella.
1996.
A transformed human tracheal gland serous cell line, MM39, that retains serous secretory functions.
Am. J. Respir. Cell Mol. Biol.
15:520-528[Abstract].
|
| 25.
|
Merten, M.
1996.
Human tracheal gland cells in primary culture, p. 201-216.
In
G. E. Jones (ed.), Methods in molecular medicine: cell culture protocols. Humana Press, Totowa, N.J.
|
| 25a.
| Merten, M. Unpublished data.
|
| 26.
|
Merten, M. D.,
J. P. Breittmayer,
C. Figarella, and C. Frelin.
1993.
ATP and UTP increase secretion of bronchial inhibitor by human tracheal gland cells in culture.
Am. J. Physiol.
265:L479-L484[Abstract/Free Full Text].
|
| 27.
|
Merten, M. D.,
A. Saleh,
W. Kammouni,
S. Marchand, and C. Figarella.
1998.
Characterization of two distinct P2Y receptors in human tracheal gland cells.
Eur. J. Biochem.
251:19-24[Medline].
|
| 28.
|
Miele, L.,
E. Cordella-Miele,
M. Xing,
R. Frizzell, and A. B. Mukherjee.
1997.
Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells.
DNA Cell Biol.
16:749-759[Medline].
|
| 29.
|
Olivier, K. N.,
W. D. Bennett,
K. W. Hohneker,
K. L. Zeman,
L. J. Edwards,
R. C. Boucher, and M. R. Knowles.
1996.
Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate ± amiloride in normal human adults.
Am. J. Respir. Crit. Care Med.
154:217-223[Abstract].
|
| 30.
|
Palfreyman, R. W.,
M. L. Watson,
C. Eden, and A. W. Smith.
1997.
Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products.
Infect. Immun.
65:617-622[Abstract].
|
| 31.
|
Parr, C. E.,
D. M. Sullivan,
A. M. Paradiso,
E. R. Lazarowski,
L. H. Burch,
J. C. Ohlsen,
L. Erb,
G. A. Weisman,
R. C. Boucher, and J. T. Turner.
1994.
Cloning and expression of a human P2u nucleotide receptor, a target for cystic fibrosis.
Proc. Natl. Acad. Sci. USA
91:3275-3279[Abstract/Free Full Text].
|
| 32.
|
Passador, L.,
J. M. Cook,
M. J. Gambello,
L. Rust, and B. H. Iglewski.
1993.
Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication.
Science
260:1127-1130[Abstract/Free Full Text].
|
| 33.
|
Pearson, J. P.,
L. Passador,
B. H. Iglewski, and E. P. Greenberg.
1995.
A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa.
Proc. Natl. Acad. Sci. USA
92:1490-1494[Abstract/Free Full Text].
|
| 34.
|
Riordan, J. R.,
J. M. Rommens,
B. S. Kerem,
N. Alon,
R. Rozmahel,
Z. Grzelczak,
J. Zielenski,
S. Lok,
N. Plavsic,
J. L. Chou,
M. L. Drumm,
M. C. Iannuzzi,
F. S. Collins, and L. C. Tsui.
1989.
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Science
245:1066-1073[Abstract/Free Full Text].
|
| 35.
|
Shaffer, C.,
K. Jacobus,
C. Foy,
C. Pue,
J. Donohue,
W. Bennet,
H. Ye,
C. Graham,
P. Noone, and D. Drutz.
1998.
Controlled clinical studies indicate that INS316 (uridine 5'-triphosphate), a P2Y2 receptor agonist, stimulates mucociliary clearance and enhances sputum expectoration.
Am. J. Respir. Crit. Care Med.
157:A796.
|
| 36.
|
Shimizu, T.,
G. C. Hannson, and B. Strandvik.
1994.
Defective inhibition by dexamethesone of leukotriene B4 and C4 production by leukocytes in patients with cystic fibrosis.
Prostaglandins Leukoc. Essent. Fatty Acids
51:407-410.
|
| 37.
|
Stickler, D. J.,
N. S. Morris,
R. J. McLean, and C. Fuqua.
1998.
Biofilms on indwelling urethral catheters produce quorum-sensing signal molecules in situ and in vitro.
Appl. Environ. Microbiol.
64:3486-3490[Abstract/Free Full Text].
|
| 38.
|
Storey, D. G.,
A. E. Ujack,
H. R. Rabin, and I. Mitchell.
1998.
Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis.
Infect. Immun.
66:2521-2528[Abstract/Free Full Text].
|
| 39.
|
Strandvik, B.,
M. Bronnegard,
H. Gilljam, and J. Carlstedt-Duke.
1988.
Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis.
Scand. J. Gastroenterol.
143(Suppl):1-4.
|
| 40.
|
Stuhlmeier, K. M.,
H. Li, and J. J. Kao.
1999.
Ibuprofen: new explanation for an old phenomenon.
Biochem. Pharmacol.
57:313-320[Medline].
|
| 41.
|
Swift, S.,
J. P. Throup,
G. P. C. Salmond,
P. Williams, and G. S. A. B. Stewart.
1996.
Quorum sensing: a population-density component in the determination of bacterial phenotype.
Trends Biochem. Sci.
21:214-219[Medline].
|
| 42.
|
Tang, H. B.,
E. DiMango,
R. Bryan,
M. Gambello,
B. H. Iglewski,
J. B. Goldberg, and A. Prince.
1996.
Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection.
Infect. Immun.
64:37-43[Abstract].
|
| 43.
|
Telford, G.,
D. Wheeler,
P. Williams,
P. T. Tomkins,
P. Appleby,
H. Sewell,
G. S. Stewart,
B. W. Bycroft, and D. I. Pritchard.
1998.
The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity.
Infect. Immun.
66:36-42[Abstract/Free Full Text].
|
| 44.
|
Tournier, J. M.,
J. Jacquot,
P. Sadoul, and J. G. Bieth.
1983.
Noncompetitive enzyme immunoassay for the measurement of bronchial inhibitor in biological fluids.
Anal. Biochem.
131:345-350[Medline].
|
| 45.
|
Ulrich, M.,
S. Herbert,
J. Berger,
G. Bellon,
D. Louis,
G. Munker, and G. Doring.
1998.
Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence.
Am. J. Respir. Cell Mol. Biol.
19:83-91[Abstract/Free Full Text].
|
| 46.
|
Wagner, J. A.,
T. V. McDonald,
P. T. Nghiem,
A. W. Lowe,
H. Schulman,
D. C. Gruenert,
L. Stryer, and P. Gardner.
1992.
Antisense oligodeoxynucleotides to the cystic fibrosis transmembrane conductance regulator inhibit cAMP-activated but not calcium-activated chloride currents.
Proc. Natl. Acad. Sci. USA
89:6785-6789[Abstract/Free Full Text].
|
| 47.
|
Winson, M. K.,
M. Camara,
A. Latifi,
M. Foglino,
S. R. Chhabra,
M. Daykin,
M. Bally,
V. Chapon,
G. P. Salmond,
B. W. Bycroft,
A. Lazdunski,
G. S. A. B. Stewart, and P. Williams.
1995.
Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa.
Proc. Natl. Acad. Sci. USA
92:9427-9431[Abstract/Free Full Text].
|
| 48.
|
Yamaya, M.,
K. Sekizawa,
Y. Kakuta,
T. Ohrui,
T. Sawai, and H. Sasaki.
1996.
P2u-purinoceptor regulation of chloride secretion in cultured human tracheal submucosal glands.
Am. J. Physiol.
270:L979-L984[Abstract/Free Full Text].
|
Infection and Immunity, October 1999, p. 5076-5082, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Miyairi, S., Tateda, K., Fuse, E. T., Ueda, C., Saito, H., Takabatake, T., Ishii, Y., Horikawa, M., Ishiguro, M., Standiford, T. J., Yamaguchi, K.
(2006). Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection.. J Med Microbiol
55: 1381-1387
[Abstract]
[Full Text]
-
Williams, S. C., Patterson, E. K., Carty, N. L., Griswold, J. A., Hamood, A. N., Rumbaugh, K. P.
(2004). Pseudomonas aeruginosa Autoinducer Enters and Functions in Mammalian Cells. J. Bacteriol.
186: 2281-2287
[Abstract]
[Full Text]
-
Tateda, K., Ishii, Y., Horikawa, M., Matsumoto, T., Miyairi, S., Pechere, J. C., Standiford, T. J., Ishiguro, M., Yamaguchi, K.
(2003). The Pseudomonas aeruginosa Autoinducer N-3-Oxododecanoyl Homoserine Lactone Accelerates Apoptosis in Macrophages and Neutrophils. Infect. Immun.
71: 5785-5793
[Abstract]
[Full Text]
-
Mathesius, U., Mulders, S., Gao, M., Teplitski, M., Caetano-Anolles, G., Rolfe, B. G., Bauer, W. D.
(2003). From the Cover: Extensive and specific responses of a eukaryote to bacterial quorum-sensing signals. Proc. Natl. Acad. Sci. USA
100: 1444-1449
[Abstract]
[Full Text]
-
Taminiau, B., Daykin, M., Swift, S., Boschiroli, M.-L., Tibor, A., Lestrate, P., De Bolle, X., O'Callaghan, D., Williams, P., Letesson, J.-J.
(2002). Identification of a Quorum-Sensing Signal Molecule in the Facultative Intracellular Pathogen Brucella melitensis. Infect. Immun.
70: 3004-3011
[Abstract]
[Full Text]
-
Erickson, D. L., Endersby, R., Kirkham, A., Stuber, K., Vollman, D. D., Rabin, H. R., Mitchell, I., Storey, D. G.
(2002). Pseudomonas aeruginosa Quorum-Sensing Systems May Control Virulence Factor Expression in the Lungs of Patients with Cystic Fibrosis. Infect. Immun.
70: 1783-1790
[Abstract]
[Full Text]
-
Smith, R. S., Harris, S. G., Phipps, R., Iglewski, B.
(2002). The Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)Homoserine Lactone Contributes to Virulence and Induces Inflammation In Vivo. J. Bacteriol.
184: 1132-1139
[Abstract]
[Full Text]
-
Forsyth, M. H., Cover, T. L.
(2000). Intercellular Communication in Helicobacter pylori: luxS Is Essential for the Production of an Extracellular Signaling Molecule. Infect. Immun.
68: 3193-3199
[Abstract]
[Full Text]